Zai Lab Ltd. ADR (ZLAB): Price and Financial Metrics
ZLAB Price/Volume Stats
| Current price | $33.40 | 52-week high | $53.95 |
| Prev. close | $30.78 | 52-week low | $20.98 |
| Day low | $32.01 | Volume | 1,004,550 |
| Day high | $33.96 | Avg. volume | 664,122 |
| 50-day MA | $34.47 | Dividend yield | N/A |
| 200-day MA | $36.45 | Market Cap | 3.27B |
ZLAB Stock Price Chart Interactive Chart >
ZLAB POWR Grades
- ZLAB scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.61% of US stocks.
- ZLAB's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- ZLAB's current lowest rank is in the Quality metric (where it is better than 8.89% of US stocks).
ZLAB Stock Summary
- For ZLAB, its debt to operating expenses ratio is greater than that reported by merely 9.12% of US equities we're observing.
- ZLAB's price/sales ratio is 14.33; that's higher than the P/S ratio of 92.59% of US stocks.
- ZLAB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 12.31% of US stocks.
- If you're looking for stocks that are quantitatively similar to ZAI LAB LTD, a group of peers worth examining would be VYNE, MIRM, PGEN, LGVN, and API.
- Visit ZLAB's SEC page to see the company's official filings. To visit the company's web site, go to www.zailaboratory.com.
ZLAB Valuation Summary
- ZLAB's EV/EBIT ratio is -6; this is 150% lower than that of the median Healthcare stock.
- Over the past 69 months, ZLAB's price/earnings ratio has gone up 28.4.
Below are key valuation metrics over time for ZLAB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZLAB | 2023-05-23 | 14.3 | 3.3 | -8.1 | -6.0 |
| ZLAB | 2023-05-22 | 14.5 | 3.3 | -8.2 | -6.1 |
| ZLAB | 2023-05-19 | 13.3 | 3.1 | -7.5 | -5.4 |
| ZLAB | 2023-05-18 | 13.3 | 3.1 | -7.5 | -5.4 |
| ZLAB | 2023-05-17 | 14.2 | 3.3 | -8.0 | -5.9 |
| ZLAB | 2023-05-16 | 14.3 | 3.3 | -8.0 | -5.9 |
ZLAB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZLAB has a Quality Grade of C, ranking ahead of 42.52% of graded US stocks.
- ZLAB's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZLAB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.071 | 0.653 | -5.744 |
| 2020-12-31 | 0.059 | 0.658 | -0.531 |
| 2020-06-30 | 0.058 | 0.727 | -0.851 |
| 2020-06-30 | 0.058 | 0.727 | -0.851 |
| 2019-12-31 | 0.040 | 0.711 | -0.887 |
| 2019-12-31 | 0.040 | 0.711 | -0.889 |
Zai Lab Ltd. ADR (ZLAB) Company Bio
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in China and around the world. Our longer-term goal is to leverage our China-based competencies and resources to enable and impact human health worldwide. (Source:ZaiLaborator)
Latest ZLAB News From Around the Web
Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.
Why Shares of Alibaba, PDD, and Zai Lab Are Rising TodaySeveral Chinese stocks rose today after positive sentiment from Wall Street and recent comments made by President Biden. |
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPASHANGHAI, China and CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). “The CDE’s decision to grant priority review to repotrectinib underscores repotrectinib as a potential |
Investors push Zai Lab (NASDAQ:ZLAB) 9.3% lower this week, company's increasing losses might be to blameIt might be of some concern to shareholders to see the Zai Lab Limited ( NASDAQ:ZLAB ) share price down 13% in the last... |
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock UpMirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track. |
Zai Lab Announces First Quarter 2023 Financial Results and Corporate UpdatesTotal product revenue of $62.8 million for the first quarter of 2023, representing a 36% increase y-o-y; ZEJULA® achieved 44% y-o-y growth Expansion of Zai Lab’s lung cancer franchise and global oncology pipeline with a next generation antibody-drug conjugate (ADC) program Strong balance sheet with a cash position of $931.4 million as of March 31, 2023, compared to $1,009.3 million as of December 31, 2022Company to host conference call and webcast on May 10, 2023, at 8:00 a.m. ET SHANGHAI and CA |
ZLAB Price Returns
| 1-mo | -4.00% |
| 3-mo | -9.56% |
| 6-mo | -8.72% |
| 1-year | 14.78% |
| 3-year | -55.11% |
| 5-year | 42.80% |
| YTD | 8.79% |
| 2022 | -51.15% |
| 2021 | -53.56% |
| 2020 | 225.41% |
| 2019 | 79.11% |
| 2018 | 9.37% |
Loading social stream, please wait...